Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US8178098B2 · kind B2 · utility
16Cited by
9References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 3, 2001 |
| Grant date | May 15, 2012 |
| Priority date | — |
| Expiry date | Feb 23, 2025 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/868
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a method to reduce airway hyperresponsivesness in an animal by the direct delivery to the lungs of aerosolized antibodies against T cell receptors. The method is particularly useful for treating airway hyperresponsiveness associated with allergic inflammation, is effective at extremely low doses of antibody, and does not have a substantial effect on the peripheral immune system.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.